Bladder Cancer is an open access journal. This means that every article, from the time it is first posted as a pre-press article to when it is included as part of an online volume, is immediately, permanently, and openly available for readers to view, download, share, and reuse. All articles published prior to 2023 are now available as open access under a CC license.
The current APC for the journal is US$1400, discounted from the full rate of US$2800.
Authors may be eligible for discounts to their APC via open access agreements that Sage has with participating institutions. Discounts depend on the terms of the agreement, find out if your institution is participating by visiting the institutional agreements page at IOS Press. Eligibility is determined by the corresponding author’s affiliation at acceptance matching an agreement.
Your article may be eligible for a full or partial waiver due to our participation in initiatives to increase accessibility to publication across the international academic community. More information about discounts and eligibility.
Policy regarding the NIH Public Access Policy mandate (PubMed Central)
All articles published in Bladder Cancer are automatically transferred to PubMed Central by the publisher within 1 month from the final publication date.
